The choice of diluent is determined by the trial sponsor, the investigational medicinal product dossier (IMPD), and the site's aseptic preparation policy not by individual preference
In addition to receptor modulation, epigenetic regulation of plasticity-related genes offers another therapeutic frontier
Nitric oxide actions in neurochemistry
In the absence of a unified conceptual framework, distinctions between neuroprotection, symptomatic treatment, and disease modification often become obscured, risking the conflation of mechanistic plausibility with demonstrable clinical benefit
The idea isnt to force results, but to introduce a steady signal for repair
Bisgaard TH, Allin KH, Keefer L, Ananthakrishnan AN, Jess T